LAUSR

The 2019 ESC guidelines on the management of patients with supraventricular tachycardia (SVT) are an update of the document published in 2003. To make their various recommendations, the authors have thoroughly reviewed the literature and evaluated the level of evidence. This article follows the order of the new guidelines document and reviews its content. The main changes in the 16 years since the publication of the previous guidelines are due to developments in catheter ablation techniques, which have become the primary treatment of choice in the chronic management of these arrhythmias. In addition, although drug therapy has not changed significantly, the relevant indications have been refined, with the disappearance of a considerable number of drug therapy-related recommendations. New therapeutic alternatives are mentioned, such as ivabradine and ibutilide, although the latter drug is not available here in Spain. Finally, recommendations are made for special situations, such as for pregnant or pediatric patients and for patients with congenital heart disease or tachycardia-induced cardiomyopathy. Table 3 of the guidelines, which contains the most representative developments and changes vs the 2003 guidelines, and Table 4, which summarizes the new recommendations, are required reading. Their contents are summarized in table 1.